BR0008188A - Inibidores de fator de diferenciação de crescimento e usos para os mesmos - Google Patents

Inibidores de fator de diferenciação de crescimento e usos para os mesmos

Info

Publication number
BR0008188A
BR0008188A BR0008188-4A BR0008188A BR0008188A BR 0008188 A BR0008188 A BR 0008188A BR 0008188 A BR0008188 A BR 0008188A BR 0008188 A BR0008188 A BR 0008188A
Authority
BR
Brazil
Prior art keywords
differentiation factor
factor inhibitors
growth differentiation
inhibitors
gdf
Prior art date
Application number
BR0008188-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Stavros Topouzis
Jill F Wright
Tamara Ratovitski
Li-Fang Liang
James L Brady Jr
Debasish Sinha
Linda Yaswen-Corkery
Original Assignee
Metamorphix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26814445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0008188(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Metamorphix Inc filed Critical Metamorphix Inc
Publication of BR0008188A publication Critical patent/BR0008188A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/30—Bird
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
BR0008188-4A 1999-01-21 2000-01-21 Inibidores de fator de diferenciação de crescimento e usos para os mesmos BR0008188A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11663999P 1999-01-21 1999-01-21
US13836399P 1999-06-10 1999-06-10
PCT/US2000/001552 WO2000043781A2 (en) 1999-01-21 2000-01-21 Growth differentiation factor inhibitors and uses therefor

Publications (1)

Publication Number Publication Date
BR0008188A true BR0008188A (pt) 2002-02-13

Family

ID=26814445

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008188-4A BR0008188A (pt) 1999-01-21 2000-01-21 Inibidores de fator de diferenciação de crescimento e usos para os mesmos

Country Status (12)

Country Link
EP (1) EP1147413B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003517580A (cg-RX-API-DMAC7.html)
CN (1) CN100567322C (cg-RX-API-DMAC7.html)
AT (1) ATE322681T1 (cg-RX-API-DMAC7.html)
AU (2) AU772694B2 (cg-RX-API-DMAC7.html)
BR (1) BR0008188A (cg-RX-API-DMAC7.html)
CA (1) CA2359242C (cg-RX-API-DMAC7.html)
DE (1) DE60027135T2 (cg-RX-API-DMAC7.html)
HK (1) HK1041521B (cg-RX-API-DMAC7.html)
MX (1) MXPA01007366A (cg-RX-API-DMAC7.html)
NZ (1) NZ513642A (cg-RX-API-DMAC7.html)
WO (1) WO2000043781A2 (cg-RX-API-DMAC7.html)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
EP0733109B9 (en) 1993-12-07 2006-07-05 Genetics Institute, LLC Bmp-12, bmp-13 and tendon-inducing compositions thereof
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
EP1790726B1 (en) * 2001-02-08 2013-07-03 Wyeth LLC Modified and stabilized GDF propeptides and uses thereof
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7629317B2 (en) 2001-03-29 2009-12-08 The University Of Chicago Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
US6734289B2 (en) 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
EP1404428B1 (en) * 2001-06-05 2006-07-19 Genetics Institute, LLC Methods for purifying highly anionic proteins
CA2453189A1 (en) * 2001-07-11 2003-01-23 Ovita Limited Bioassay for myostatin
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
AU2003301195B2 (en) * 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
JP2007530055A (ja) 2004-03-26 2007-11-01 アクセルロン ファーマ インコーポレーテッド Bmp−3プロペプチドおよび関連する方法
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
EP1771557B1 (en) 2004-06-24 2014-12-31 Acceleron Pharma Inc. GDF3 Propeptides and Related Methods
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII受容体ポリペプチド、方法、および組成物
BRPI0513914A (pt) * 2004-07-29 2008-05-20 Schering Plough Ltd uso de inibidores do alk 5 para modular ou inibir a atividade da miostatina acarretando um acréscimo maior de tecido magro em animais
EP1864139A2 (en) * 2005-03-23 2007-12-12 Wyeth Detection of an immune response to gdf-8 modulating agents
MX2007011400A (es) * 2005-03-23 2007-10-11 Wyeth Corp Deteccion de agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8).
US8017576B2 (en) 2005-05-10 2011-09-13 The University Of Chicago Methods and compositions to treat mucositis
US7888486B2 (en) 2005-08-19 2011-02-15 Wyeth Llc Antagonist antibodies against GDF-8
KR101135220B1 (ko) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
BRPI0618947B1 (pt) 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
HRP20130320T1 (en) 2006-09-05 2013-05-31 Eli Lilly And Company Anti-myostatin antibodies
CA2672758C (en) 2006-12-18 2019-07-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TWI584815B (zh) 2007-02-01 2017-06-01 艾瑟勒朗法瑪公司 活化素-ActRIIa拮抗劑及其治療或預防乳癌之用途
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
MX2009008510A (es) 2007-02-09 2010-01-15 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US9610327B2 (en) 2007-03-06 2017-04-04 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PE20150680A1 (es) 2008-11-26 2015-05-16 Amgen Inc Variantes de polipeptidos receptores de activina iib y aplicaciones de estos
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
KR102170682B1 (ko) 2009-08-13 2020-10-28 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 gdf 트랩과 에리트로포이에틴 수용체 활성인자의 병용
NZ599604A (en) * 2009-10-01 2014-07-25 Myostin Therapeutics Pty Ltd Synthetic myostatin peptide antagonists
EP3260130B1 (en) 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
DK3520805T3 (da) 2011-10-17 2021-04-19 Acceleron Pharma Inc Sammensætninger til behandling af myelofibrose
MY177331A (en) 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
EP4678239A3 (en) 2012-08-01 2026-04-08 Ikaika Therapeutics, Inc. Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
JP6457942B2 (ja) 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ, インコーポレイテッド Gdf−8阻害剤
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
KR20150136061A (ko) 2013-02-01 2015-12-04 산타 마리아 바이오테라퓨틱스, 인코포레이티드 대상에 항-액티빈-a 화합물의 투여
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
EP3131931B1 (en) 2014-04-18 2020-10-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
JP6568110B2 (ja) 2014-06-04 2019-08-28 アクセルロン ファーマ, インコーポレイテッド フォリスタチンポリペプチドによる障害の処置のための方法および組成物
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3221318B1 (en) 2014-11-21 2021-08-25 Rigel Pharmaceuticals, Inc. Fused imidazole derivatives as tgf-beta inhibitors
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP3259264B1 (en) 2015-02-20 2022-07-27 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
JP6836998B2 (ja) 2015-03-02 2021-03-03 ライジェル ファーマシューティカルズ, インコーポレイテッド TGF−β阻害剤
US11021468B2 (en) 2015-04-01 2021-06-01 Rigel Pharmaceuticals, Inc. TGF-ß inhibitors
EP3277673B1 (en) 2015-04-01 2022-05-04 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CN113683708A (zh) 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
EP3280435B1 (en) 2015-04-06 2021-06-02 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
CA2983440C (en) 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
EP3370754B1 (en) 2015-11-04 2026-04-29 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
JP7072507B2 (ja) 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
LT3490582T (lt) 2016-07-27 2024-07-25 Acceleron Pharma Inc. Kompozicijos, skirtos naudoti gydant mielofibrozę
AU2017338916B2 (en) 2016-10-05 2022-03-24 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
WO2018067740A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma, Inc. Compositions and method for treating kidney disease
CN110678195A (zh) 2016-10-05 2020-01-10 阿塞勒隆制药公司 ALK4:ActRIIB异多聚体及其用途
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
AU2019262139A1 (en) 2018-05-03 2020-11-26 Acceleron Pharma Inc. Multispecific binders of TGFβ-superfamily ligands and uses thereof
AU2019406214A1 (en) 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
EP3995153A4 (en) * 2019-06-26 2023-11-22 KNC Laboratories Co., Ltd. Nucleic acid drug suppressing production of myostatin gene mrna

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254678A (en) * 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
CA2157577C (en) * 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US5616466A (en) * 1993-11-05 1997-04-01 Cantor; Glenn H. Ribozyme-mediated inhibition of bovine leukemia virus
DE69534468T2 (de) * 1994-07-08 2006-07-13 The Johns Hopkins University School Of Medicine Wachstums-differenzierungsfaktor-11
US6008434A (en) * 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US5674748A (en) * 1995-03-14 1997-10-07 Thomas Jefferson University Human cyclin-dependent kinase-like proteins and methods of using the same
US6124115A (en) * 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
WO1998024925A1 (en) * 1995-11-08 1998-06-11 Medical University Of South Carolina Tissue specific and target rna-specific ribozymes as antimicrobial therapeutics against microbial pathogens
US5824519A (en) * 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
AU6274298A (en) * 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
NO971997D0 (no) * 1997-04-29 1997-04-29 Kjetil Tasken Bruk av immunmodulerende midler
WO1999002667A1 (en) * 1997-07-14 1999-01-21 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
WO1999006559A1 (en) * 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
NZ509609A (en) * 1998-07-28 2003-11-28 Univ Johns Hopkins Med Disrupting growth differentiation factor-11 (GDF-11) to increase the muscle and bone tissue in animals

Also Published As

Publication number Publication date
CA2359242A1 (en) 2000-07-27
CA2359242C (en) 2009-12-08
EP1147413B1 (en) 2006-04-05
AU2514000A (en) 2000-08-07
WO2000043781A3 (en) 2001-02-01
HK1041521B (en) 2006-11-17
NZ513642A (en) 2004-02-27
HK1041521A1 (en) 2002-07-12
EP1147413A2 (en) 2001-10-24
DE60027135T2 (de) 2007-01-11
CN1355881A (zh) 2002-06-26
DE60027135D1 (de) 2006-05-18
ATE322681T1 (de) 2006-04-15
AU2004203398A1 (en) 2004-08-19
JP2003517580A (ja) 2003-05-27
CN100567322C (zh) 2009-12-09
WO2000043781A2 (en) 2000-07-27
MXPA01007366A (es) 2002-06-04
AU772694B2 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
ATE322681T1 (de) Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
BR0210839A (pt) Sistema de recombinação, método para remover uma sequência de dna do dna cromossÈmico de uma célula ou organismo eucarióticos, organismo, cultura de célula, órgão, tecido, parte ou material de propagação transgênico, e, uso de um organismo ou de uma cultura de célula, órgão, tecido, parte ou material de propagação transgênico
EA200700382A1 (ru) Фунгицидные композиции
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
CY1117672T1 (el) Αναστολεις της ανθρωπινης δελτα φωσφατιδυλ-ινοσιτολ-3-κινασης
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
AR011539A1 (es) DERIVADOS DE BENZOILO-3-HETEROCICLIL-SUSTITUIDOS, PROCEDIMIENTO PARA SU PREPARACIoN,COMPUESTOS INTERMEDIARIOS DE APLICACIoN EN DICHO PROCEDIMIENTO, COMPOSICIONES QUE COMPRENDEN DICHOS DERIVADOS, Y PROCEDIMIENTO PARA SU PREPARACIoN, PROCEDIMIENTO PARA COMBATIR VEGETACIoN NO DESADA QUE LOS EMPLEA Y SU
NO20030381L (no) Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
DK0725790T3 (da) Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
BR0212809A (pt) Inibidores de anticorpos de gdf-8 e usos dos mesmos
EP1328519A4 (en) OPTICALLY ACTIVE SALTS WITH TYROSINKINASE ACTIVITY
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
BR9811099A (pt) Inibidores de urocinase
DE60234329D1 (de) Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
BR0107884A (pt) Derivados de imida substituìdos
ATE345354T1 (de) Methode zur identifizierung von helicobacter antigenen
EP1218398A4 (en) ANTISENSE MODULATION OF P13 KINASE P110 BETA EXPRESSION
AR010565A1 (es) Moleculas de acido nucleico aislados, proteina aislada, formulaciones que las contienen, composicion terapeutica, uso de un compuesto protector y uninhibidor para preparar una composicion terapeutica, metodo para producir una proteina de carboxilesterosa, metodo para identificar compuestos, equipo d
BG101038A (bg) Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък
BR0014314A (pt) Processo para derivados de ácido fenilacético
CY1119579T1 (el) Μεθοδος για τη θεραπεια διαταραχων αναπτυξης της τριχας, οπως η γυναικειου τυπου αλωπεκια και συνεπως χρησιμα σκευασματα
ES2191211T3 (es) Uso de acido peracetico en piscicultura.
ATE327980T1 (de) 3-heterocyclyl-substituierte benzoesäurederivate

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 (IX), 13 E 18 (III) DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.